Ionis Pharmaceuticals (IONS) Set to Release Earnings on Wednesday

Key Points

• Ionis Pharmaceuticals is expected to report Q3 2026 results before market open on Wednesday, November 4. Analysts anticipate a loss of $1.22 per share and revenue of approximately $181.56 million.
• IONS opened at $43.68, near its 52-week low of $42.08 and well below its 52-week high of $86.74. The company’s market capitalization is approximately $7.26 billion.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $89.48; 19 analysts rate the stock a Buy, compared with three Holds and one Sell.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($1.22) per share and revenue of $181.56 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 10:30 AM ET.

Ionis Pharmaceuticals Stock Performance

IONS opened at $43.68 on Wednesday. Ionis Pharmaceuticals has a fifty-two week low of $42.08 and a fifty-two week high of $86.74. The company has a fifty day moving average of $49.95 and a two-hundred day moving average of $67.38. The stock has a market capitalization of $7.26 billion, a price-to-earnings ratio of -12.63 and a beta of 0.38.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IONS shares. UBS Group assumed coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, October 15th. They set a "buy" rating and a $88.00 target price on the stock. BMO Capital Markets upgraded Ionis Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $54.00 to $66.00 in a research note on Thursday, October 22nd. JPMorgan Chase & Co. reduced their price target on Ionis Pharmaceuticals from $76.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, September 22nd. Citigroup reaffirmed a "buy" rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 21st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $86.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, September 4th. Nineteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $89.48.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Shannon L. Devers sold 1,357 shares of the firm's stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the transaction, the executive vice president directly owned 17,811 shares of the company's stock, valued at $775,490.94. This trade represents a 7.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden bought 15,000 shares of the stock in a transaction dated Thursday, July 30th. The shares were bought at an average price of $53.38 per share, for a total transaction of $800,700.00. Following the completion of the acquisition, the director owned 19,000 shares in the company, valued at approximately $1,014,220. The trade was a 375.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 1.81% of the company's stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing medicines using antisense technology. Its platform is designed to selectively target RNA and regulate the production of disease-related proteins. The company develops therapies for neurological, cardiovascular and metabolic, and rare diseases.

Ionis has developed and commercialized medicines both independently and through collaborations with larger pharmaceutical companies. Its marketed or partnered products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin amyloidosis, and Tryngolza (olezarsen) for familial chylomicronemia syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.